Tratamiento farmacológico de los tumores neuroendocrinos gastroenteropancreáticos: análogos de somatostatina

Interferon-alpha is indicated in patientswith somatostatin analog resistance, especially in carcinoids. Chemotherapy should be considered in poorly differentiated tumors or in patients with progressive disease and no response to somatostatin analogs and/or interferon. The risk-benefit ratio of using aggressive therapy should always be considered in patients who, despite having disseminated disease, usually have prolonged survival.